ProMab is a biotech company developing recombinant proteins and custom monoclonal antibodies through the integration of bioinformatics, gene cloning, protein expression and purification, and immunology, using novel high-throughput technologies.
Promab – custom rabbit monoclonal antibody
Promab Biotechnologies is a biotech company created to meet the post-genomics needs. Promab applies its proprietary proteins and antibodies to deliver innovative diagnostic products as well as services targeting the global biomedical market through collaborations with other biotechnology and bio-reagent companies. Promab has successfully generated approximately 3000 custom monoclonal antibodies over the past 11 years. Indeed, Promab offers a three-phase reliable and affordable rat and mouse hybridoma development services for producing custom monoclonal antibodies. The aim of a Promab Biotechnologies custom monoclonal antibody project is not only to generate an antibody that recognizes the immunizing antigen, but to raise an antibody that works for your specific application. Promab also provides in vivo ascites production services which can be used as an alternative for monoclonal antibody production. Ascites production is one of the most cost effective and efficient ways of generating large quantities of specific monoclonal antibodies.
Interestingly, Promab now offers a four-phase, custom rabbit monoclonal antibody service. Promab proposes a platform to generate custom recombinant rabbit monoclonal antibodies. ProMab’s highly technical staff, with decades of experience spanning immunology, microbiology, biochemistry, cell and molecular biology will be there to guide you through the vital process of designing an appropriate antigen, and the subsequent, and equally important step of designing a strategy required for the generation of a truly successful, and validated antibody.
Moreover, antibodies required for therapeutic use are required to be structurally indistinct to other endogenous circulating human antibodies, so as to minimize immunogenicity following their introduction into the patient. Promab Biotechnologies offers customers the choice of two distinct strategies to afford production of human custom antibodies for therapeutic use. The humanization of non-human antibodies, requiring the modification of the complementarity-determining regions (CDRs) to increase their similarity to human antibody variants. Promab also offers a completely human Fab library, constituting sequences derived from the antibody repertoire of approximately 120 individuals, with a diversity/complexity of approximately 1 x 1011 clones.
Founded and managed by a team of scientists with extensive experience in both academic and industrial biotechnology, ProMab Biotechnologies is headquartered in the USA. Pro-Mab Biotechnologies seeks partnership with academic researchers, biotechnology and pharmaceutical companies around the world. And Promab also offers a wide range of cancer stem cell products and services including cancer stem cell antibodies, cancer stem cell media and cancer stem cell markers.
More about Pro mab : www.promab.com